At the time of writing, Tandem Diabetes Care Inc [TNDM] stock is trading at $31.12, up 8.74%. An important factor to consider is whether the stock is rising or falling in short-term value. The TNDM shares have gain 5.35% over the last week, with a monthly amount glided 28.12%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 18, March 2024, Parexel Announces CEO Succession Plan. In a post published today on Yahoo Finance, Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024.
From an analyst’s perspective:
Tandem Diabetes Care Inc [NASDAQ: TNDM] stock has seen the most recent analyst activity on August 04, 2023, when Citigroup downgraded its rating to a Neutral and also revised its price target to $33 from $45. Previously, BofA Securities downgraded its rating to Underperform on May 05, 2023, and dropped its price target to $33. On April 24, 2023, downgrade downgraded it’s rating to Mkt Perform. UBS started tracking the stock assigning a Neutral rating and suggested a price target of $45 on March 29, 2023. Wolfe Research initiated its recommendation with a Peer Perform. Wells Fargo upgraded its rating to Equal Weight for this stock on November 15, 2022, but kept the price target unchanged to $43. In a note dated October 18, 2022, Barclays initiated an Overweight rating and provided a target price of $75 on this stock.
For the past year, the stock price of Tandem Diabetes Care Inc fluctuated between $13.82 and $44.05. Currently, Wall Street analysts expect the stock to reach $119 within the next 12 months. Tandem Diabetes Care Inc [NASDAQ: TNDM] shares were valued at $31.12 at the most recent close of the market. An investor can expect a potential return of 282.39% based on the average TNDM price forecast.
Analyzing the TNDM fundamentals
According to Tandem Diabetes Care Inc [NASDAQ:TNDM], the company’s sales were 747.72M for trailing twelve months, which represents an -10.75% plunge. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.69 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.44 points at the first support level, and at 27.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.99, and for the 2nd resistance point, it is at 32.86.
Tandem Diabetes Care Inc [TNDM] reported earnings per share of -$0.27 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.25/share, meaning a difference of -$0.02 and a surprise factor of -8.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.38 per share as compared to estimates of -$0.34 per share, a difference of -$0.04 representing a surprise of -11.80%.
Ratios To Look Out For
It is important to note that Tandem Diabetes Care Inc [NASDAQ:TNDM] has a current ratio of 3.83. On the other hand, the Quick Ratio is 3.02, and the Cash Ratio is 0.3. Considering the valuation of this stock, the price to sales ratio is 2.73, the price to book ratio is 6.50.
Transactions by insiders
Recent insider trading involved Allen Dick, Director, that happened on Nov 27 ’23 when 5000.0 shares were purchased. EVP & CHIEF FINANCIAL OFFICER, Vosseller Leigh completed a deal on Nov 08 ’23 to buy 6200.0 shares. Meanwhile, Chief Legal Officer Hansen Shannon Marie bought 1935.0 shares on Nov 08 ’23.
